Pyruvate Kinase, Erythrocytes
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Work-up of cases of nonspherocytic hemolytic anemia
Investigating families with pyruvate kinase deficiency to determine inheritance pattern and for genetic counseling
Kinetic Spectrophotometry (KS)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Pyruvate Kinase, RBC
PK (Pyruvate Kinase)
Pyruvate Kinase (RBC)
Pyruvate Kinase (RBC)
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Preferred: Yellow top (ACD solution B)
Specimen Volume: 6 mL
Collection Instructions: Do not transfer blood to other containers.
Forms: If not ordering electronically, please submit a Hematopathology/Molecular Oncology Request Form (Supply T241) with the specimen.
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Mild OK; Gross reject
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
|Whole blood||Refrigerated||20 days|
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Deficiencies of most of the enzymes of the Embden-Meyerhof (glycolytic) pathway, including pyruvate kinase (PK), have been reported. PK deficiency, although rare, is the erythrocyte enzyme deficiency most frequently found to be a cause of congenital nonspherocytic hemolytic anemia. It is an autosomal recessive disorder. Thus, the parents of affected patients are heterozygotes. Patients usually present during early childhood with anemia, icterus, and splenomegaly. Hemolytic disease of the newborn is common in persons with PK deficiency.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
6.7-14.3 U/g hemoglobin
Most pyruvate kinase (PK) deficient patients have 5% to 25% of normal activity.
Elevated PK concentrations can be found in those patients with younger erythrocyte population. This may be due to the patient being a newborn or young red cells are being produced in response to the anemia (reticulocytosis).
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Because leukocytes also contain pyruvate kinase (PK) that is not diminished in hereditary erythrocytic PK deficiency, freeing the blood of white blood cells is always critical to this test.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
Beutler E: Hereditary nonspherocytic hemolytic anemia: pyruvate kinase deficiency and other abnormalities. In Hematology. Fourth edition. Edited by WJ Williams, E Beutler, AJ Erslev, MA Lichtman. New York, McGraw-Hill Information Services Company, Health Professions Division, 1990, pp 606-612
Method Description Describes how the test is performed and provides a method-specific reference
A red cell hemolysate is incubated with adenosine diphosphate and phosphoenolpyruvate. The amount of pyruvate formed is quantitated by adding lactic dehydrogenase and reduced nicotinamide adenine di-nucleotide and measuring the rate of decrease in absorbance at 340 nm.(Beutler E: Red Cell Metabolism. In A Manual of Biochemical Methods. Third edition. New York, Grune and Stratton, 1984, pp 68-71)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Saturday
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
|Result ID||Reporting Name||LOINC Code|
|PK_||Pyruvate Kinase, RBC||32552-2|